| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-10-08 | Coronado Biosciences (USA - MA) Journey Medical Corporation (USA - AZ) | establishment of a new subsidiary in the US |
Dermatological diseases | Establishment of a new subsidiary in the US | ||
| 2014-10-08 | Cardio3 BioSciences (Belgium) Mayo Clinic (USA - MN) | collaboration |
Regenerative medicine - Cardiovascular diseases | Collaboration agreement | ||
| 2014-10-08 | Saniona (Denmark) Ataxion (USA - MA) | ataxia | development |
Neuromuscular diseases | Development agreement | |
| 2014-10-07 | BIA (UK) Bionow (UK) BioPartner (UK) One Nucleus (UK) | United Life Sciences | collaboration |
Collaboration agreement | ||
| 2014-10-07 | Merck Serono, a Merck KGaA company (Germany) The Institute of Cancer Research (ICR) (UK) the Wellcome Trust (UK) | inhibitors of tankyrase | development licensing |
Cancer - Oncology | Development agreement | |
| 2014-10-07 | Oncobiologics (USA - NJ) | member of the board of directors | nomination | Nomination | ||
| 2014-10-06 | Ariad Pharmaceuticals (USA - MA) Bellicum Pharmaceuticals (USA - TX) | cell-signaling technology | licensing |
Licensing agreement | ||
| 2014-10-06 | Novartis (Switzerland) BMS (USA - NY) | Opdivo® (nivolumab), Zykadia® (ceritinib), INC280, EGF816 | non-small cell lung cancer | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2014-10-06 | Horizon Discovery (UK) Haplogen Genomics (Austria) | CRISPR/Cas9 human haploid cell line generation service and human haploid knock-out cell lines catalog | distribution |
Technology - Services | Distribution agreement | |
| 2014-10-06 | ARTES Biotechnology (Germany) instrAction (Germany) Q-Biologicals (Belgium) | collaboration |
Veterinary medicine | Collaboration agreement | ||
| 2014-10-06 | CleveXel Pharma (France) SATT SE (France) | triazole nucleoside derivatives (TND) and companion diagnostic test | azacitidine-resistant myelodysplastic syndromes | licensing |
Cancer - Oncology | Licensing agreement |
| 2014-10-03 | Ophthotech (USA - NY) | chief commercial officer | nomination | Nomination | ||
| 2014-10-03 | Ceva Santé Animale (France) | new industrial facility in Libourne | opening of new premises | Veterinary medicine | Opening of new premises | |
| 2014-10-02 | Menarini (Italy) Oxford BioTherapeutics (UK) | portfolio of antibody and antibody drug conjugate (ADC) programs in the field of cancer | cancer | R&D |
Cancer - Oncology | Development agreement |
| 2014-10-02 | VolitionRx (Singapore) MD Anderson Cancer Center’s Department of Genitourinary Medical Oncology (USA - TX) | NuQ®assays | prostate cancer | Cancer - Oncology | Collaboration agreement | |
| 2014-10-02 | Servier (France) Walter and Eliza Hall Institute (Australia) | Mcl-1-inhibitory BH3-mimetics | R&D |
Cancer - Oncology | R&D agreement | |
| 2014-10-01 | Bayer (Germany) Merck&Co (USA - NJ) | Adempas™ (riociguat), vericiguat and other sGC modulators presently in earlier stages of R&D | collaboration |
Cardiovascular diseases | Collaboration agreement | |
| 2014-10-01 | Novartis (Switzerland) Enanta Pharmaceuticals (USA - MA) | EDP-239 | hepatitis C | licensing development manufacturing production commercialisation |
Infectious diseases | Termination of an agreement |
| 2014-10-01 | The Lead Discovery Center (LDC) (Germany) UiT The Arctic University of Norway (Norway) | new medicines from the marine arctic environment | Collaboration agreement | |||
| 2014-10-01 | Hybrigenics (France) | Illumina® NextSeq500® sequencer | acquisition |
Product acquisition |
